Organization Profile

You just read:

RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus

News provided by

Resverlogix Corp.

Sep 02, 2014, 08:30 ET